TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7990071

Group type: EXPERIMENTAL
Intervention: Posture biofeedback (PB)
Number of subjects: 27
Study: 2921588

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 1.5 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 3.0 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 6.0 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (all doses)
Number of subjects: 0
Study: 808231

Group type: EXPERIMENTAL
Intervention: Glipizide (2.5 mg, single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glibenclamide (single dose)
Number of subjects: 12
Study: 31424177

Group type: EXPERIMENTAL
Intervention: SurE (surfactant without endotracheal tube intubation)
Number of subjects: 350

Group type: COMPARATOR
Intervention: InSurE technique (intubation surfactant and extubation)
Number of subjects: 350
Study: 28240013

Group type: EXPERIMENTAL
Intervention: Physical therapy with biofeedback training
Number of subjects: 13

Group type: COMPARATOR
Intervention: Physical therapy without biofeedback training (Control)
Number of subjects: 13
Study: 25409877

Group type: EXPERIMENTAL
Intervention: Light salt (3 g daily for 4 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Regular salt (3 g daily for 4 weeks)
Number of subjects: 35
Study: 23585522

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care regimens
Number of subjects: 0
Study: 21911312

Group type: EXPERIMENTAL
Intervention: Group 1 (660nm/15mW/3.8J/cm(2)/spot size 4mm(2))
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group 2 (660nm/5mW/1.3J/cm(2)/spot size 4mm(2))
Number of subjects: 70
Study: 19536124

Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16441604

Group type: EXPERIMENTAL
Intervention: Apheresis platelets
Number of subjects: 22

Group type: COMPARATOR
Intervention: PRP platelets
Number of subjects: 22
Study: 15324525

Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 66
Study: 10903458

Group type: EXPERIMENTAL
Intervention: Rapid Four-Step Technique (RFST) using a Bair Claw
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard open technique
Number of subjects: 2
Study: 9269942

Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 12
Study: 7683989

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Transurethral resection (TURP)
Number of subjects: 79
Study: 3498395

Group type: EXPERIMENTAL
Intervention: Propofol injection at 15 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol injection at 30 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol injection at 45 seconds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 29314455

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) ≤112 mmHg
Number of subjects: 28771

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) 113-120 mmHg
Number of subjects: 28771

Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) >125 mmHg
Number of subjects: 28771

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) highest quintile
Number of subjects: 28771
Study: 27571124

Group type: EXPERIMENTAL
Intervention: Mucosyte (verbascoside, polyvinylpyrrolidone, sodium hyaluronate), 3 mouthwashes/day for 8 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (inert water-based solution), 3 mouthwashes/day for 8 days
Number of subjects: 56
Study: 25219129

Group type: EXPERIMENTAL
Intervention: Acu + Rehab (warm-reinforcing needling combined with Bobath rehabilitation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehab (Bobath rehabilitation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acu + Rehab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehab
Number of subjects: 60
Study: 23898483

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 100 mg/kg orally, pre-treated 10 days before and 5 days after ADR treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adriamycin (ADR) 20 mg/kg i.p.
Number of subjects: 0
Study: 20204604

Group type: EXPERIMENTAL
Intervention: Daily cholecalciferol 800 IU + calcium 1,000 mg for 3 years
Number of subjects: 593

Group type: COMPARATOR
Intervention: Neither supplementation nor placebo
Number of subjects: 593
Study: 18568230

Group type: EXPERIMENTAL
Intervention: Implant-supported overdenture (IP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional denture (CD)
Number of subjects: 53
Study: 16630670

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1500 mg/m2 on days 1 and 8 every 3 weeks by standard 30 min intravenous infusion (arm A)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Gemcitabine 10 mg/m2/min for 150 min on days 1 and 8 every 3 weeks by intravenous infusion at fixed dose rate (arm B)
Number of subjects: 121
Study: 12747194

Group type: EXPERIMENTAL
Intervention: Huang Lian Sheng Mai Yin
Number of subjects: 357
Study: 10966698

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 180

Group type: COMPARATOR
Intervention: Oral iodinated contrast medium
Number of subjects: 180
Study: 8991324

Group type: EXPERIMENTAL
Intervention: Resilient Peer Treatment (RPT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study: 7948800

Group type: EXPERIMENTAL
Intervention: Sotalol (1 mg/kg loading infusion over 2 hours, followed by 0.15 mg/kg/h for 24 hours, then 80 mg orally every 8 or 12 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no sotalol)
Number of subjects: 42
Study: 2451883

Group type: EXPERIMENTAL
Intervention: BCAP (bleomycin, cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 45

Group type: COMPARATOR
Intervention: BP (bleomycin plus cisplatin)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BCAP
Number of subjects: 45

Group type: COMPARATOR
Intervention: BP
Number of subjects: 45
Study: 29573648

Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 29072016

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion combined with kegel exercise therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Simple kegel exercise therapy
Number of subjects: 45
Study: 26253933

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study: 23916916

Group type: EXPERIMENTAL
Intervention: FITT‐C intervention (telephone-based psychosocial intervention for 6 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non‐directive telephone support (control group)
Number of subjects: 250
Study: 21247733

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Higher HDL cholesterol
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Smoking (in women)
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Higher non-HDL cholesterol
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Lower HDL cholesterol
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Low levels of diastolic pressure and BMI
Number of subjects: 1266
Study: 18165850

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb761) 120 mg twice per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16933459

Group type: EXPERIMENTAL
Intervention: Controlled gum chewing exercise protocol for eight weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Support and encouragement
Number of subjects: 20
Study: 12928941

Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®) as monotherapy or in combination with methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anakinra (Kineret®) combined with anti-TNF agents
Number of subjects: 0
Study: 11118091

Group type: EXPERIMENTAL
Intervention: Valaciclovir prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2113258

Group type: EXPERIMENTAL
Intervention: Dyclonine hydrochloride 1.0% (Dyclone)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Viscous lidocaine with 1% cocaine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Kaolin-pectin solution, diphenhydramine plus saline (KBS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study: 483371

Group type: EXPERIMENTAL
Intervention: Steroid treatment in addition to a standard regime
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard regime without steroids
Number of subjects: 52
Study: 31992219

Group type: EXPERIMENTAL
Intervention: Exoskeleton-based gait rehabilitation program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual physical therapy care
Number of subjects: 40
Study: 31149999

Group type: EXPERIMENTAL
Intervention: Paravertebral analgesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 40
Study: 28547735

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 2385

Group type: EXPERIMENTAL
Intervention: Probable Medication-Overuse Headache (pMOH)
Number of subjects: 2385

Group type: EXPERIMENTAL
Intervention: Any headache yesterday (HY)
Number of subjects: 2385

Group type: EXPERIMENTAL
Intervention: Overall headache disability
Number of subjects: 2385
Study: 26033941

Group type: EXPERIMENTAL
Intervention: Individualised cognitive functional therapy (CFT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Combined exercise and pain education class
Number of subjects: 214
Study: 23548162

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 872

Group type: COMPARATOR
Intervention: Control intervention (non-specific general information about the role of stress in heart disease)
Number of subjects: 872
Study: 21898340

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 800 mg once daily for 6 months
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 19573383

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone solution (Iintropin AQ)
Number of subjects: 31
Study: 16706763

Group type: EXPERIMENTAL
Intervention: ClozeX
Number of subjects: 15

Group type: COMPARATOR
Intervention: suture
Number of subjects: 15
Study: 14716192

Group type: EXPERIMENTAL
Intervention: Educational video on osteoporosis
Number of subjects: 195

Group type: COMPARATOR
Intervention: Routine physician visit (control)
Number of subjects: 195
Study: 11466602

Group type: EXPERIMENTAL
Intervention: Anti-obesity surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative patient education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient knowledge, psychosocial adaptation, and motivational factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life after bariatric surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staged approach to bariatric surgery
Number of subjects: 0
Study: 9040450

Group type: EXPERIMENTAL
Intervention: Combination of 50 mg losartan and 10 mg enalapril
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 12

Group type: COMPARATOR
Intervention: 20 mg enalapril
Number of subjects: 12
Study: 7738214

Group type: EXPERIMENTAL
Intervention: 200 mg/m2/hr DDTC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 mg/m2/hr DDTC
Number of subjects: 15
Study: 3189700

Group type: EXPERIMENTAL
Intervention: Intravenous crystalline penicillin for 5 days
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intravenous fluids only (Control)
Number of subjects: 79
Study: 30894162

Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lecture (traditional lecture-style education)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (simulation and lecture)
Number of subjects: 76
Study: 28640017

Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall incidence of reparalysis
Number of subjects: 64
Study: 25530111

Group type: EXPERIMENTAL
Intervention: Revexepride (0.5 mg, three times daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 24179976

Group type: EXPERIMENTAL
Intervention: Immediate loading (test group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Early loading (control group)
Number of subjects: 80
Study: 22008690

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg intravenously) + 0.25% ropivacaine (2 mL per incision, 6 mL total)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg intravenously) + 0.5% ropivacaine (2 mL per incision, 6 mL total)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no analgesics administered)
Number of subjects: 80
Study: 19691368

Group type: EXPERIMENTAL
Intervention: MPA(t) concentrations
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Reduction in CL(CR) from 60 to 25 mL/min
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Accumulation of MPAG(t) concentrations from 50 to 150 mg/L
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Decrease in plasma albumin concentration from 40 to 30 g/L
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: MPA(u) clearance
Number of subjects: 88
Study: 17005801

Group type: EXPERIMENTAL
Intervention: Daptomycin 10 mg/kg once daily for 14 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daptomycin 12 mg/kg once daily for 14 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 or 8 mg/kg once daily for 4 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daptomycin (various doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daptomycin up to 12 mg/kg intravenously for 14 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14533665

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 microg twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Montelukast, 5 mg/d
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 22
Study: 10928575

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9635271

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA) - loading dose 15 mg/kg, continuous infusion 10 mg/kg per hour for 6 hours
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - loading dose 15 mg/kg, continuous infusion 1 mg/kg per hour for 6 hours
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal saline infusion for 6 hours
Number of subjects: 59
Study: 1392155

Group type: EXPERIMENTAL
Intervention: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group A: vindesine (2.5 mg/m2 day 1 and 8), mitoxantrone (12 mg/m2/day) every 4 weeks, mitomycin C (8 mg/m2) every 8 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: VMMC protocol (vindesine, mitoxantrone, mitomycin C) - Group B: vindesine (2.5 mg/m2), mitoxantrone (12 mg/m2) every 3 weeks on day 1, mitomycin C (8 mg/m2) every 6 weeks
Number of subjects: 103
Study: 3912735

Group type: EXPERIMENTAL
Intervention: Grenz rays (4 Gy applied on 6 occasions at intervals of 1 week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment (control side)
Number of subjects: 16
Study: 29976505

Group type: EXPERIMENTAL
Intervention: Patients treated at sites with major RTQA violations (n=86)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Patients treated at sites without major violations
Number of subjects: 554
Study: 26673433

Group type: EXPERIMENTAL
Intervention: ATX-101 (2 mg/cm)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 25348000

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus lapatinib
Number of subjects: 295

Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus lapatinib (HER2-positive tumors)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Fulvestrant plus placebo (HER2-positive tumors)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus lapatinib (HER2-normal tumors)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Fulvestrant plus placebo (HER2-normal tumors)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for fulvestrant plus lapatinib
Number of subjects: 295

Group type: COMPARATOR
Intervention: Overall survival (OS) for fulvestrant plus placebo
Number of subjects: 295
Study: 21296903

Group type: EXPERIMENTAL
Intervention: 12.5% discount on healthier foods
Number of subjects: 1104

Group type: EXPERIMENTAL
Intervention: Tailored nutrition education
Number of subjects: 1104

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1104
Study: 19741509

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (ASA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 40
Study: 17196359

Group type: EXPERIMENTAL
Intervention: SmokeStopTherapy (SST)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: minimal intervention strategy for lung patients (LMIS)
Number of subjects: 225
Study: 15040966

Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM) technique
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 14
Study: 11228032

Group type: EXPERIMENTAL
Intervention: Conservative management with medication, physiotherapy, or bracing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study: 9158511

Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg epirubicin in 50 mL normal saline immediately after TURBT
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 50 mg epirubicin in 50 mL normal saline 1-2 weeks after TURBT, repeated for 8 weeks and thereafter monthly for one year
Number of subjects: 168

Group type: COMPARATOR
Intervention: No adjuvant therapy after TURBT (control group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Single-dose epirubicin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with epirubicin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both treated groups
Number of subjects: 168
Study: 8119091

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol) applied as a spray (1 ml) at the end of the operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 30
Study: 3116982

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during nitrendipine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine infusion (12.5, 25 and 50 ng/kg/min) during placebo
Number of subjects: 0
Study: 352705

Group type: EXPERIMENTAL
Intervention: Oral mexiletine 600 mg daily for 1 week
Number of subjects: 10

Group type: COMPARATOR
Intervention: No active drug (placebo)
Number of subjects: 10
Study: 31608711

Group type: EXPERIMENTAL
Intervention: creatine 30 g/day (CRE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tamoxifen 40 mg/day (T40)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tamoxifen 80 mg/day (T80)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 31338198

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28032568

Group type: EXPERIMENTAL
Intervention: 7-day intensive preoperative pulmonary rehabilitation (PR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional preoperative respiratory management (NPR)
Number of subjects: 60
Study: 25351788

Group type: EXPERIMENTAL
Intervention: 0.2 g kg(‐1) ammonia chloride (ACD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.3 g kg(‐1) calcium carbonate (PLA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.3 g kg(‐1) sodium bicarbonate (ALK)
Number of subjects: 8
Study: 23962878

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) programme, high compliance tertile
Number of subjects: 4556

Group type: COMPARATOR
Intervention: Control group (low compliance tertile)
Number of subjects: 4556
Study: 21337251

Group type: EXPERIMENTAL
Intervention: Spa treatment (combined sauna, cold water immersion, and jacuzzi) after the first match for post-PHV players
Number of subjects: 28

Group type: COMPARATOR
Intervention: No specific between-match recovery intervention (control) for post-PHV players
Number of subjects: 28
Study: 19767791

Group type: EXPERIMENTAL
Intervention: 20 mg diazepam (HIGH)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (LOW)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 15
Study: 18212651

Group type: EXPERIMENTAL
Intervention: Dynamic Condylar Screw (DCS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Russell‐Taylor Reconstruction Nail (RTRN)
Number of subjects: 66
Study: 15476225

Group type: EXPERIMENTAL
Intervention: Subtalar-strapped insole
Number of subjects: 66

Group type: COMPARATOR
Intervention: Traditional wedged insole
Number of subjects: 66
Study: 11532885

Group type: EXPERIMENTAL
Intervention: Dual RT tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single RT tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual RT tasks that interfere
Number of subjects: 0